Dr.Roberto Collazo-Maldonado retweeted
#Sparsentan as First-Line Treatment in #IgAN: Promising #SPARTAN Results
Phase 2 trial at 24 weeks:
🔹 ~70% reduction in proteinuria
🔹 58% achieved proteinuria remission
🔹 Generally stable eGFR
🔹 Potential anti-inflammatory & antifibrotic effects
@ISNkidneycare @AfricanAFRAN
Dr.Roberto Collazo-Maldonado retweeted
Los Rookies en el equipo inmunosupresor para #IgAN
🏈 Ofensiva: los inhibidores de BAFF/APRIL
Con los resultados a 2 años:
- Sibeprenlimab
-Atacicept
-Telitacicept
El recién llegado: povetacicept
🏈Defensiva: los inhibidores del complemento
-Ravulizumab
-Sefarsexen
#ActualizameIMIN26 #SemanaIMIN26 #IMIN #IgAN
Dr.Roberto Collazo-Maldonado retweeted
#DiagnoseThis! What is your diagnosis in this native kidney biopsy?
#renalpath #kidneypath #pathology #renal #DiagnoseThis!
Today is the Rank Order List Certification Deadline for the Medicine and Pediatric Specialties Match! Certify your ROL by 9 p.m. ET. The #NRMP support team is available until 9 p.m. ET to help with questions. Good luck! @_pedsubs @APPDconnect #MedEd
ow.ly/blbV510596H
Dr.Roberto Collazo-Maldonado retweeted
CELEBRATING EXCELLENCE AT DNA!
We are proud to announce that 15 of our physicians have been recognized as D Magazine’s Best Doctors in Dallas County for 2026! Join us in congratulating these remarkable physicians! We are grateful for the difference they make every day!
Dr.Roberto Collazo-Maldonado retweeted
Nephro power 💪🏻💪🏻
The authors analyze the degree to which clinical specialties are shielded from, or threatened by, AI depending on how much of their work requires in-person physical interaction. Learn more: nejm.ai/3UDkrIv

ALT Bar chart titled "Limits to AI Substitution across Specialties: Composition of Medicare Part B Payments Including E&M Services." The chart shows percentages of "Physical," "E&M," and "Nonphysical" services across 15 medical specialties and all overall (US$44.9bn). Total 2023 Medicare Part B payments are shown in parentheses (US$ bn); amounts are in billions of U.S. dollars.
Dr.Roberto Collazo-Maldonado retweeted
Pt with massive proteinuria (20g), AKI, history of IV drug use, chemo/radiation and artificial joint for malignancy, multiple infections. Massive amyloidosis, AA type. #renalpath #pathtwitter #nephrology
Dr.Roberto Collazo-Maldonado retweeted
🚨 Obinutuzumab: first FDA-approved therapy for adults with primary membranous nephropathy
MAJESTY trial: complete proteinuria remission at week 104:
🔹 Obinutuzumab: 36%
🔹 Tacrolimus: 6%
Antigen-based classification is reshaping our understanding
🤖 Made with AI
Dr.Roberto Collazo-Maldonado retweeted
DNA is proud to sponsor the Texas Indo-American Physicians Society (TIPS) Northeast Chapter 2026 Gala! The evening will feature a special tribute to Dr. Anupkumar Shetty, honoring his contributions to the care of dialysis patients in the DFW area. #TIPS
Dr.Roberto Collazo-Maldonado retweeted
Today, FDA approved the first drug to treat adults with primary membranous nephropathy, a rare kidney disease where the immune system attacks the kidney's filtering units, causing serious complications. This milestone reflects our continued commitment to patients with rare diseases.
fda.gov/drugs/news-events-hu…

ALT FDA Drug Approval graphic with text reading "FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy." The navy blue square graphic includes the FDA logo in the upper right corner, a gold "Drug Approval" banner in the upper left, and icons of medication bottles, capsules, and a syringe along the bottom.
Dr.Roberto Collazo-Maldonado retweeted
#ASNKidney360 An 18-year-old developed KDIGO stage 3 AKI after minimal naproxen exposure. Pharmacogenetic testing revealed a CYP2C92/2 genotype associated with reduced NSAID metabolism, underscoring a potentially underrecognized contributor to NSAID-associated nephrotoxicity. kidney.pub/KID1431
Dr.Roberto Collazo-Maldonado retweeted
nature.com/articles/s41584-0… The PANLAR-GLADEL guidelines for treatment of SLE are now available! An important step for Latin America
Dr.Roberto Collazo-Maldonado retweeted
This Veterans Day, DNA honors all who have served.
Thank you for your courage, sacrifice, and dedication to our country. We are grateful today and every day.
#VeteransDay #ThankYouVeterans
Dr.Roberto Collazo-Maldonado retweeted
🎆 Fogos de artifício, cantos e a #alegria de um milhão de fiéis! E o #PapaLeãoXIV também canta, enquanto contempla a festa dos jovens que ilumina a noite de Buenos Aires!
Foi assim que terminou a #Vigília de Oração realizada nesta terça-feira (10/11), na Argentina
Dr.Roberto Collazo-Maldonado retweeted
Hace 98 años nació un hombre que con su música lo cambió todo para siempre, ese hombre se llamaba Ennio Morricone.
Eterno.
Dr.Roberto Collazo-Maldonado retweeted
Ironic that the one study showed 4 episodes of blindness in 136,000 patients with placebo or diabetes and 6 in 136,000 and the FDA is now asking for a warning. Is that statistically meaningful to carry a label. It’s not mechanistically clear. What we do know is that there is a 20% reduction in major adverse cardiovascular events in the select trial at four years in a large prospective study using glp1 meds. And that heart disease is the number one cause of mortality worldwide. In the properly selected patients, under physician supervision, they are becoming the standard of care.
The risk of blindness associated with GLP-1 drugs is ~2/100,000 people taking these drugs and properly noted by @FDA, the very rare condition known as NAION
wsj.com/health/pharma/u-s-re… by @AlexLJanin
Dr.Roberto Collazo-Maldonado retweeted
I’m at the @UpToDate Editors meeting today. I’ve been an author/section editor for 20 years. The breaking news is UpToDate Expert AI.
Check out UpToDate Expert AI at your institutions. You should have access if you have access to UpToDate.
UpToDate Expert AI is unique. It is AI plus the world’s top experts analysis and interpretation rolled into one. It offers AI’s magic and proficiency with the human expert element added.
In my experience AI is incredibly helpful but very few of us rely solely on AI to make clinical decisions for a serious illness. Patients still want input from the human expert. Thats what makes UpToDate Expert AI unique. It has both. That helps the treating physician make the best management choice for their patient.
Dr.Roberto Collazo-Maldonado retweeted
💬 Viewpoint by Hanny Al-Samkari, MD, Scott Olitsky, MD, and Michael Auerbach, MD: The new
FDA boxed warning for #FerricCarboxymaltose identifies a significant risk of #Hypophosphatemia and related complications, including osteomalacia, fractures, cardiac arrhythmias, and neuromuscular dysfunction.
The warning follows a successful FDA Citizen Petition and adds regulatory attention to adverse effects associated with intravenous iron treatment.
ja.ma/4etMmRP
Dr.Roberto Collazo-Maldonado retweeted
The FDA is informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. FDA fda.gov/safety/medical-produ…








































